Association of PPI with survival outcomes in the whole study population and in each treatment arm
| PPI and treatment . | OS, months . | PFS, months . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median (95% CI) . | Univariate analysis . | Stratified analysis . | Median (95% CI) . | Univariate analysis . | Stratified analysis . | |||||
| uHR (95% CI) . | p value . | aHR . | p value . | uHR . | p value . | aHR . | p value . | |||
| All (n = 482) | ||||||||||
| Non-PPI user | 16 (15–18) | 1 (Ref) | .80 | 1 (Ref) | .32 | 8 (7–9) | 1 (Ref) | .40 | 1 (Ref) | .11 |
| PPI user | 17 (13–21) | 1.04 (0.75–1.44) | 0.85 (0.61–1.18) | 10 (6–12) | 0.88 (0.64–1.19) | 0.77 (0.56–1.06) | ||||
| FOLFIRI (n = 243) | ||||||||||
| Non-PPI user | 15 (13–17) | 1 (Ref) | .24 | 1 (Ref) | .011 | 7 (6–9) | 1 (Ref) | .12 | 1 (Ref) | .020 |
| PPI user | 19 (10–30) | 0.75 (0.46–1.22) | 0.50 (0.30–0.85) | 10 (5–16) | 0.70 (0.45–1.10) | 0.55 (0.33–0.91) | ||||
| mXELIRI (n = 239) | ||||||||||
| Non-PPI user | 16 (15–20) | 1 (Ref) | .093 | 1 (Ref) | .22 | 8 (7–9) | 1 (Ref) | .62 | 1 (Ref) | .65 |
| PPI user | 16 (12–21) | 1.46 (0.94–2.26) | 1.32 (0.84–2.08) | 8 (5–12) | 1.11 (0.73–1.70) | 1.11 (0.71–1.74) | ||||
| PPI and treatment . | OS, months . | PFS, months . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median (95% CI) . | Univariate analysis . | Stratified analysis . | Median (95% CI) . | Univariate analysis . | Stratified analysis . | |||||
| uHR (95% CI) . | p value . | aHR . | p value . | uHR . | p value . | aHR . | p value . | |||
| All (n = 482) | ||||||||||
| Non-PPI user | 16 (15–18) | 1 (Ref) | .80 | 1 (Ref) | .32 | 8 (7–9) | 1 (Ref) | .40 | 1 (Ref) | .11 |
| PPI user | 17 (13–21) | 1.04 (0.75–1.44) | 0.85 (0.61–1.18) | 10 (6–12) | 0.88 (0.64–1.19) | 0.77 (0.56–1.06) | ||||
| FOLFIRI (n = 243) | ||||||||||
| Non-PPI user | 15 (13–17) | 1 (Ref) | .24 | 1 (Ref) | .011 | 7 (6–9) | 1 (Ref) | .12 | 1 (Ref) | .020 |
| PPI user | 19 (10–30) | 0.75 (0.46–1.22) | 0.50 (0.30–0.85) | 10 (5–16) | 0.70 (0.45–1.10) | 0.55 (0.33–0.91) | ||||
| mXELIRI (n = 239) | ||||||||||
| Non-PPI user | 16 (15–20) | 1 (Ref) | .093 | 1 (Ref) | .22 | 8 (7–9) | 1 (Ref) | .62 | 1 (Ref) | .65 |
| PPI user | 16 (12–21) | 1.46 (0.94–2.26) | 1.32 (0.84–2.08) | 8 (5–12) | 1.11 (0.73–1.70) | 1.11 (0.71–1.74) | ||||
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; FOLFIRI, leucovorin, fluorouracil, and irinotecan; mXELIRI, modified capecitabine plus irinotecan; OS, overall survival; PFS, progression-free survival; PPI, proton pump inhibitor; uHR, unadjusted hazard ratio.
Association of PPI with survival outcomes in the whole study population and in each treatment arm
| PPI and treatment . | OS, months . | PFS, months . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median (95% CI) . | Univariate analysis . | Stratified analysis . | Median (95% CI) . | Univariate analysis . | Stratified analysis . | |||||
| uHR (95% CI) . | p value . | aHR . | p value . | uHR . | p value . | aHR . | p value . | |||
| All (n = 482) | ||||||||||
| Non-PPI user | 16 (15–18) | 1 (Ref) | .80 | 1 (Ref) | .32 | 8 (7–9) | 1 (Ref) | .40 | 1 (Ref) | .11 |
| PPI user | 17 (13–21) | 1.04 (0.75–1.44) | 0.85 (0.61–1.18) | 10 (6–12) | 0.88 (0.64–1.19) | 0.77 (0.56–1.06) | ||||
| FOLFIRI (n = 243) | ||||||||||
| Non-PPI user | 15 (13–17) | 1 (Ref) | .24 | 1 (Ref) | .011 | 7 (6–9) | 1 (Ref) | .12 | 1 (Ref) | .020 |
| PPI user | 19 (10–30) | 0.75 (0.46–1.22) | 0.50 (0.30–0.85) | 10 (5–16) | 0.70 (0.45–1.10) | 0.55 (0.33–0.91) | ||||
| mXELIRI (n = 239) | ||||||||||
| Non-PPI user | 16 (15–20) | 1 (Ref) | .093 | 1 (Ref) | .22 | 8 (7–9) | 1 (Ref) | .62 | 1 (Ref) | .65 |
| PPI user | 16 (12–21) | 1.46 (0.94–2.26) | 1.32 (0.84–2.08) | 8 (5–12) | 1.11 (0.73–1.70) | 1.11 (0.71–1.74) | ||||
| PPI and treatment . | OS, months . | PFS, months . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median (95% CI) . | Univariate analysis . | Stratified analysis . | Median (95% CI) . | Univariate analysis . | Stratified analysis . | |||||
| uHR (95% CI) . | p value . | aHR . | p value . | uHR . | p value . | aHR . | p value . | |||
| All (n = 482) | ||||||||||
| Non-PPI user | 16 (15–18) | 1 (Ref) | .80 | 1 (Ref) | .32 | 8 (7–9) | 1 (Ref) | .40 | 1 (Ref) | .11 |
| PPI user | 17 (13–21) | 1.04 (0.75–1.44) | 0.85 (0.61–1.18) | 10 (6–12) | 0.88 (0.64–1.19) | 0.77 (0.56–1.06) | ||||
| FOLFIRI (n = 243) | ||||||||||
| Non-PPI user | 15 (13–17) | 1 (Ref) | .24 | 1 (Ref) | .011 | 7 (6–9) | 1 (Ref) | .12 | 1 (Ref) | .020 |
| PPI user | 19 (10–30) | 0.75 (0.46–1.22) | 0.50 (0.30–0.85) | 10 (5–16) | 0.70 (0.45–1.10) | 0.55 (0.33–0.91) | ||||
| mXELIRI (n = 239) | ||||||||||
| Non-PPI user | 16 (15–20) | 1 (Ref) | .093 | 1 (Ref) | .22 | 8 (7–9) | 1 (Ref) | .62 | 1 (Ref) | .65 |
| PPI user | 16 (12–21) | 1.46 (0.94–2.26) | 1.32 (0.84–2.08) | 8 (5–12) | 1.11 (0.73–1.70) | 1.11 (0.71–1.74) | ||||
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval; FOLFIRI, leucovorin, fluorouracil, and irinotecan; mXELIRI, modified capecitabine plus irinotecan; OS, overall survival; PFS, progression-free survival; PPI, proton pump inhibitor; uHR, unadjusted hazard ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
